Silverback Therapeutics Inc. (SBTX): Price and Financial Metrics


Silverback Therapeutics Inc. (SBTX): $3.24

0.21 (+6.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SBTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SBTX Stock Price Chart Interactive Chart >

Price chart for SBTX

SBTX Price/Volume Stats

Current price $3.24 52-week high $35.63
Prev. close $3.03 52-week low $2.80
Day low $3.05 Volume 318,400
Day high $3.26 Avg. volume 377,590
50-day MA $3.39 Dividend yield N/A
200-day MA $8.97 Market Cap 113.87M

Silverback Therapeutics Inc. (SBTX) Company Bio


Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.


SBTX Latest News Stream


Event/Time News Detail
Loading, please wait...

SBTX Latest Social Stream


Loading social stream, please wait...

View Full SBTX Social Stream

Latest SBTX News From Around the Web

Below are the latest news stories about Silverback Therapeutics Inc that investors may wish to consider to help them evaluate SBTX as an investment opportunity.

Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

SEATTLE, February 24, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.

Yahoo | February 24, 2022

Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SEATTLE, February 03, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022.

Yahoo | February 3, 2022

5AM Venture Management, LLC Buys Pear Therapeutics Inc, Entrada Therapeutics Inc, Sells ...

Investment company 5AM Venture Management, LLC (Current Portfolio) buys Pear Therapeutics Inc, Entrada Therapeutics Inc, sells Crinetics Pharmaceuticals Inc, Avidity Biosciences Inc, Silverback Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 5AM Venture Management, LLC.

Yahoo | February 3, 2022

Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference

SEATTLE, January 05, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.

Yahoo | January 5, 2022

Deadline Tuesday Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

DEADLINE TUESDAY NOTICE : The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encou

Yahoo | January 1, 2022

Read More 'SBTX' Stories Here

SBTX Price Returns

1-mo N/A
3-mo -22.67%
6-mo -60.10%
1-year -88.63%
3-year N/A
5-year N/A
YTD -51.35%
2021 -85.63%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6737 seconds.